Kymera Therapeutics – Market Performance and Upcoming Financial Disclosure
Kymera Therapeutics (NASDAQ: KYMR) closed the trading day on Friday, 23 March 2026, at USD 110.76, a decline of 0.73 % relative to the previous session. The stock price is currently trading within a range that reflects a 52‑week high of USD 130.05 (recorded on 25 June 2026) and a 52‑week low of USD 55.66 (recorded on 4 November 2025).
Current Market Metrics
- Current price: USD 110.76
- Shares outstanding: 83.2 million
- Market capitalization: USD 9.4 billion
- Volume traded in last 24 hours: USD 116.6 million
- Simple moving average (200 days): USD 94.9
- Performance since previous month‑end: down 7.73 %
Kymera’s share price moved in line with the broader trend of clinical‑stage biopharmaceuticals, which have experienced modest volatility over the past 24 hours.
Upcoming Financial Announcement
Kymera Therapeutics will release its third‑quarter 2026 financial results on 29 October 2026. The company has scheduled a video conference and live webcast to discuss the results; a replay of the event will be available after the broadcast. The disclosure is expected to provide insight into the company’s progress in developing oral small‑molecule degraders for immunological diseases and into the status of its first degrader in clinical trials.
Industry Context
Kymera operates in a competitive landscape dominated by firms developing targeted protein degradation technologies. Its pipeline targets conditions that are not amenable to conventional therapies, positioning the company as an innovator within the Boston biopharmaceutical ecosystem.
Comparative Stock Performance (Last 24 Hours)
| Ticker | Price Change | Current Price | Market Cap | Notable Corporate Development |
|---|---|---|---|---|
| ARW (Arrow Electronics) | -4.44 % | USD 209.76 | USD 11.2 bn | No significant event reported. |
| PSKY (Skydance) | +10.85 % | USD 7.77 | USD 11 bn | Elon Musk’s investment of approximately USD 1 bn to support cost reduction and asset consolidation. |
| COO (Cooper Cos / The) | +4.54 % | USD 61.21 | USD 11.2 bn | Board re‑designations and approval of interim dividend for FY 2026‑27. |
| MOH (Molina Healthcare) | +0.81 % | USD 209.15 | USD 11.2 bn | Q3 2026 results fell short of FY 2025; guidance for FY 2026 maintained. |
| ELAN (Elanco Animal Health) | -0.66 % | USD 22.52 | USD 11.2 bn | Appointment of Jamie Preston as Executive VP and Chief People Officer; transition plan with retiring Dave Kinard. |
Company Profile – Kymera Therapeutics
Kymera Therapeutics, Inc. specializes in the discovery and development of small‑molecule therapeutics that selectively degrade disease‑causing proteins by harnessing the body’s natural protein degradation pathways. The company is headquartered in Watertown, United States, operates in the health‑care sector, and is listed on the Nasdaq stock exchange. Further information can be found on the company’s website: www.kymeratx.com .
